Several clinical trials have provided evidence implicating the CXCL1/CXCR2 axis as a therapeutic target for asthma, bronchiectasis, and cancer, with promising effects in chronic obstructive pulmonary disorder (COPD) [40]. The gene discussed is CXCR2; the disease is cancer.